$83 Million Series A Financing to Fuel Development of Gamma-Delta T Cell Engager

Cytospire Therapeutics, a UK-based biotech company, has successfully raised $83 million (approximately £61 million) in a Series A funding round. The round was co-led by 4BIO Capital and Servier Pharmaceuticals' venture arm, with participation from Abingworth and other investors, totaling seven institutions. This investment reflects strong market confidence in the next-generation immuno-oncology technology based on gamma-delta T cells, aiming to overcome the limitations of conventional T cell engagers (TCEs) in solid tumors.

Limitations of Existing CD3-Targeting T Cell Engagers and Differentiated Mechanism

Currently approved T cell engagers, such as Amgen's Blincyto, primarily target the CD3 receptor expressed on all T cells, inducing potent anti-cancer effects. However, these therapies have shown limitations in solid tumors, often causing severe toxicity. A key issue is cytokine release syndrome (CRS) and attacks on normal tissues due to excessive immune activation, necessitating dose reductions. In contrast, Cytospire's platform selectively mobilizes gamma-delta T cells, overcoming the tumor microenvironment (TME) and simultaneously activating both innate and adaptive immunity. This approach enhances the safety profile by more precisely distinguishing between normal and cancer cells.

Lead Pipeline, CYT X300: Target, Preclinical Results, and Clinical Plans

Cytospire's lead pipeline, 'CYT X300,' is a pan-gamma delta T cell engager that targets the epidermal growth factor receptor (EGFR) and simultaneously activates all gamma-delta T cell subtypes (Vδ1, Vδ2, Vδ3). In preclinical studies, CYT X300, currently in the preclinical stage, demonstrated excellent tolerability in non-human primates, without causing severe CRS or systemic toxicity, unlike conventional CD3-based engagers. The company plans to use the newly secured funding to conduct research for Investigational New Drug (IND) submission, establish global manufacturing processes, and initiate a first-in-human clinical trial in patients with EGFR-positive colorectal cancer, head and neck cancer, and non-small cell lung cancer (NSCLC).

Potential of the Solid Tumor Targeted Immuno-Oncology Market and Competitive Landscape

The global EGFR-targeted therapy market is estimated at $8.2 billion to $16.1 billion, driven by the increasing incidence of non-small cell lung cancer patients. The T cell engager market is also projected to grow rapidly, exceeding $18.7 billion by the mid-2030s. Consequently, the development of next-generation T cell engagers targeting solid tumors is highly competitive, with companies like Janux Therapeutics (JANX007) and LAVA Therapeutics developing gamma-delta-targeting pipelines. Cytospire's innovative mechanism has the potential to be a game-changer by achieving both safety and efficacy, attracting significant industry attention for potential partnerships or licensing agreements with major pharmaceutical companies.